COHEN & STEERS INC (CNS) Stock Fundamental Analysis
NYSE:CNS - New York Stock Exchange, Inc. - US19247A1007 - Common Stock - Currency: USD
We assign a fundamental rating of 6 out of 10 to CNS. CNS was compared to 227 industry peers in the Capital Markets industry. Both the health and profitability get an excellent rating, making CNS a very profitable company, without any liquidiy or solvency issues. CNS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CNS was profitable.
CNS had a positive operating cash flow in the past year.
CNS had positive earnings in each of the past 5 years.
Each year in the past 5 years CNS had a positive operating cash flow.
1.2 Ratios
CNS has a better Return On Assets (18.62%) than 98.68% of its industry peers.
Looking at the Return On Equity, with a value of 29.56%, CNS belongs to the top of the industry, outperforming 94.71% of the companies in the same industry.
The Return On Invested Capital of CNS (22.68%) is better than 98.68% of its industry peers.
CNS had an Average Return On Invested Capital over the past 3 years of 28.30%. This is significantly above the industry average of 7.09%.
The last Return On Invested Capital (22.68%) for CNS is well below the 3 year average (28.30%), which needs to be investigated, but indicates that CNS had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.62% | ||
| ROE | 29.56% | ||
| ROIC | 22.68% |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
1.3 Margins
The Profit Margin of CNS (29.23%) is better than 70.04% of its industry peers.
In the last couple of years the Profit Margin of CNS has declined.
The Operating Margin of CNS (33.41%) is comparable to the rest of the industry.
CNS's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 88.96%, CNS belongs to the top of the industry, outperforming 92.07% of the companies in the same industry.
CNS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.41% | ||
| PM (TTM) | 29.23% | ||
| GM | 88.96% |
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
2. Health
2.1 Basic Checks
CNS has more shares outstanding than it did 1 year ago.
CNS has more shares outstanding than it did 5 years ago.
CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 8.71 indicates that CNS is not in any danger for bankruptcy at the moment.
CNS has a Altman-Z score of 8.71. This is amongst the best in the industry. CNS outperforms 95.15% of its industry peers.
CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.71 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
CNS has a Current Ratio of 1.13. This is a normal value and indicates that CNS is financially healthy and should not expect problems in meeting its short term obligations.
CNS's Current ratio of 1.13 is in line compared to the rest of the industry. CNS outperforms 53.74% of its industry peers.
CNS has a Quick Ratio of 1.13. This is a normal value and indicates that CNS is financially healthy and should not expect problems in meeting its short term obligations.
CNS has a Quick ratio (1.13) which is in line with its industry peers.
CNS does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.13 | ||
| Quick Ratio | 1.13 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 7.58% over the past year.
Measured over the past 5 years, CNS shows a small growth in Earnings Per Share. The EPS has been growing by 2.50% on average per year.
CNS shows a small growth in Revenue. In the last year, the Revenue has grown by 5.67%.
Measured over the past years, CNS shows a small growth in Revenue. The Revenue has been growing by 4.72% on average per year.
EPS 1Y (TTM)7.58%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%7.14%
Revenue 1Y (TTM)5.67%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%9.58%
3.2 Future
CNS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.77% yearly.
CNS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.51% yearly.
EPS Next Y14.1%
EPS Next 2Y7.14%
EPS Next 3Y9.99%
EPS Next 5Y11.77%
Revenue Next Year4.43%
Revenue Next 2Y5.54%
Revenue Next 3Y7.06%
Revenue Next 5Y5.51%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 23.90 indicates a rather expensive valuation of CNS.
64.32% of the companies in the same industry are cheaper than CNS, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 28.29. CNS is around the same levels.
The Price/Forward Earnings ratio is 21.18, which indicates a rather expensive current valuation of CNS.
Based on the Price/Forward Earnings ratio, CNS is valued a bit more expensive than 62.11% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.32. CNS is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.9 | ||
| Fwd PE | 21.18 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CNS is valued a bit cheaper than 71.37% of the companies in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as CNS.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 42.69 | ||
| EV/EBITDA | 19.57 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of CNS may justify a higher PE ratio.
PEG (NY)1.7
PEG (5Y)9.57
EPS Next 2Y7.14%
EPS Next 3Y9.99%
5. Dividend
5.1 Amount
CNS has a Yearly Dividend Yield of 3.34%.
Compared to an average industry Dividend Yield of 8.41, CNS has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.51, CNS pays a bit more dividend than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.34% |
5.2 History
The dividend of CNS decreases each year by -7.12%.
CNS has been paying a dividend for at least 10 years, so it has a reliable track record.
CNS has decreased its dividend in the last 3 years.
Dividend Growth(5Y)-7.12%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
CNS pays out 78.79% of its income as dividend. This is not a sustainable payout ratio.
DP78.79%
EPS Next 2Y7.14%
EPS Next 3Y9.99%
71.22
-3.04 (-4.09%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners60.13%
Inst Owner Change0.29%
Ins Owners23.14%
Ins Owner Change1.15%
Market Cap3.63B
Analysts76.67
Price Target94.35 (32.48%)
Short Float %6.72%
Short Ratio8.38
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.34% |
Yearly Dividend2.39
Dividend Growth(5Y)-7.12%
DP78.79%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.31%
Min EPS beat(2)-2.26%
Max EPS beat(2)-0.35%
EPS beat(4)1
Avg EPS beat(4)-1.13%
Min EPS beat(4)-2.38%
Max EPS beat(4)0.49%
EPS beat(8)3
Avg EPS beat(8)0.63%
EPS beat(12)7
Avg EPS beat(12)1.24%
EPS beat(16)11
Avg EPS beat(16)3.26%
Revenue beat(2)1
Avg Revenue beat(2)-2.56%
Min Revenue beat(2)-11.33%
Max Revenue beat(2)6.21%
Revenue beat(4)1
Avg Revenue beat(4)-2.18%
Min Revenue beat(4)-11.33%
Max Revenue beat(4)6.21%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.6%
PT rev (3m)-13.15%
EPS NQ rev (1m)2.7%
EPS NQ rev (3m)-10.06%
EPS NY rev (1m)5.75%
EPS NY rev (3m)-7.88%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.9 | ||
| Fwd PE | 21.18 | ||
| P/S | 7.02 | ||
| P/FCF | 42.69 | ||
| P/OCF | 37.54 | ||
| P/B | 7.09 | ||
| P/tB | 7.36 | ||
| EV/EBITDA | 19.57 |
EPS(TTM)2.98
EY4.18%
EPS(NY)3.36
Fwd EY4.72%
FCF(TTM)1.67
FCFY2.34%
OCF(TTM)1.9
OCFY2.66%
SpS10.15
BVpS10.04
TBVpS9.67
PEG (NY)1.7
PEG (5Y)9.57
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.62% | ||
| ROE | 29.56% | ||
| ROCE | 29.55% | ||
| ROIC | 22.68% | ||
| ROICexc | 33% | ||
| ROICexgc | 37.88% | ||
| OM | 33.41% | ||
| PM (TTM) | 29.23% | ||
| GM | 88.96% | ||
| FCFM | 16.44% |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
ROICexc(3y)52.58%
ROICexc(5y)66.96%
ROICexgc(3y)63.61%
ROICexgc(5y)82.87%
ROCE(3y)36.88%
ROCE(5y)49.77%
ROICexcg growth 3Y-36.94%
ROICexcg growth 5Y-14.2%
ROICexc growth 3Y-34.4%
ROICexc growth 5Y-13.57%
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 104.32% | ||
| Cap/Sales | 2.25% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 52.54% | ||
| Profit Quality | 56.22% | ||
| Current Ratio | 1.13 | ||
| Quick Ratio | 1.13 | ||
| Altman-Z | 8.71 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)429.54%
Cap/Depr(5y)277.84%
Cap/Sales(3y)4.88%
Cap/Sales(5y)3.14%
Profit Quality(3y)59.63%
Profit Quality(5y)81.14%
High Growth Momentum
Growth
EPS 1Y (TTM)7.58%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%7.14%
EPS Next Y14.1%
EPS Next 2Y7.14%
EPS Next 3Y9.99%
EPS Next 5Y11.77%
Revenue 1Y (TTM)5.67%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%9.58%
Revenue Next Year4.43%
Revenue Next 2Y5.54%
Revenue Next 3Y7.06%
Revenue Next 5Y5.51%
EBIT growth 1Y5.11%
EBIT growth 3Y-12.76%
EBIT growth 5Y1.55%
EBIT Next Year50.56%
EBIT Next 3Y24.45%
EBIT Next 5Y7.49%
FCF growth 1Y-26.04%
FCF growth 3Y-29.26%
FCF growth 5Y-9.31%
OCF growth 1Y-43.77%
OCF growth 3Y-26.44%
OCF growth 5Y-7.32%